{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T17:41:00Z","timestamp":1770918060469,"version":"3.50.1"},"reference-count":23,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,12,7]],"date-time":"2016-12-07T00:00:00Z","timestamp":1481068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004191","name":"Novo Nordisk","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004191","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","diabetesresearchclinicalpractice.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Diabetes Research and Clinical Practice"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.diabres.2016.11.028","type":"journal-article","created":{"date-parts":[[2016,12,10]],"date-time":"2016-12-10T01:35:58Z","timestamp":1481333758000},"page":"209-217","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["Exploring the characteristics of suboptimally controlled patients after 24 weeks of basal insulin treatment: An individualized approach to intensification"],"prefix":"10.1016","volume":"123","author":[{"given":"Kamlesh","family":"Khunti","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taner","family":"Damci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lise Lotte","family":"Husemoen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinay","family":"Babu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Liebl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.diabres.2016.11.028_b0005","article-title":"AACE\/ACE comprehensive diabetes management algorithm","volume":"21","year":"2015","journal-title":"Endocr Pract"},{"key":"10.1016\/j.diabres.2016.11.028_b0010","first-page":"S1","article-title":"Standard of Medical Care in Diabetes\u20132016","volume":"39","author":"American Diabetes Association","year":"2016","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.11.028_b0015","unstructured":"National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NG28. December 2015."},{"key":"10.1016\/j.diabres.2016.11.028_b0020","doi-asserted-by":"crossref","first-page":"3411","DOI":"10.2337\/dc13-0331","article-title":"Clinical inertia in people with type 2 diabetes: a retrospective cohort study of more than 80,000 people","volume":"36","author":"Khunti","year":"2013","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.11.028_b0025","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJMoa1006524","article-title":"Long-term effects of intensive glucose lowering on cardiovascular outcomes","volume":"364","author":"Gerstein","year":"2011","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.diabres.2016.11.028_b0030","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1056\/NEJMoa0905479","article-title":"Three-year efficacy of complex insulin regimens in type 2 diabetes","volume":"361","author":"Holman","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.diabres.2016.11.028_b0035","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.2337\/diacare.28.11.2673","article-title":"Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study","volume":"28","author":"Peyrot","year":"2005","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.11.028_b0040","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1477-7525-7-91","article-title":"Fear of hypoglycaemia: defining a minimum clinically important difference in patients with type 2 diabetes","volume":"7","author":"Stargardt","year":"2009","journal-title":"Health Qual Life Outcomes"},{"issue":"Suppl. 1","key":"10.1016\/j.diabres.2016.11.028_b0045","doi-asserted-by":"crossref","first-page":"S11","DOI":"10.1016\/S1751-9918(10)60004-6","article-title":"Addressing barriers to initiation of insulin in patients with type 2 diabetes","volume":"4","author":"Peyrot","year":"2010","journal-title":"Prim Care Diabetes"},{"key":"10.1016\/j.diabres.2016.11.028_b0050","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1111\/j.1463-1326.2009.01060.x","article-title":"Patient-directed titration for achieving glycaemic goals using a once-daily basal insulin analogue: an assessment of two different fasting plasma glucose targets \u2013 the TITRATETM study","volume":"11","author":"Blonde","year":"2009","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.11.028_b0055","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1111\/j.1463-1326.2012.01665.x","article-title":"The safety and efficacy of adding once-daily insulin detemir to oral hypoglycaemic agents in patients with type 2 diabetes in a clinical practice setting in 10 countries","volume":"14","author":"Khunti","year":"2012","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.11.028_b0060","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/dom.12626","article-title":"Clinical inertia with regard to intensifying therapy in people with type 2 diabetes treated with basal insulin","volume":"18","author":"Khunti","year":"2016","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.11.028_b0065","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s00125-014-3460-0","article-title":"Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes","volume":"58","author":"Inzucchi","year":"2015","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2016.11.028_b0070","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.diabres.2015.02.034","article-title":"Predictors of HbA1c over 4 years in people with type 2 diabetes starting insulin therapies: the CREDIT study","volume":"108","author":"Balkau","year":"2015","journal-title":"Diabetes Res Clin Prac"},{"key":"10.1016\/j.diabres.2016.11.028_b0075","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.2337\/dc13-2413","article-title":"Predictive and explanatory factors of change in HbA1c in a 24-week observational study of 66,726 people with type 2 diabetes starting insulin analogs","volume":"37","author":"Home","year":"2014","journal-title":"Diabetes Care"},{"issue":"9","key":"10.1016\/j.diabres.2016.11.028_b0080","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/dom.12096","article-title":"Baseline HbA1c predicts attainment of 7.0% HbA1c target with structured titration of insulinglargine in type 2 diabetes: a patient-level analysis of 12 studies","volume":"15","author":"Riddle","year":"2013","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.11.028_b0085","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1007\/s00125-007-0911-x","article-title":"A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-na\u00efve people with type 2 diabetes","volume":"51","author":"Rosenstock","year":"2008","journal-title":"Diabetologia"},{"key":"10.1016\/j.diabres.2016.11.028_b0090","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/j.clinthera.2006.10.020","article-title":"Comparison of once-daily insulin detemir with NPH insulin added to a regimen of oral antidiabetic drugs in poorly controlled type 2 diabetes","volume":"28","author":"Philis-Tsimikas","year":"2006","journal-title":"Clin Ther"},{"key":"10.1016\/j.diabres.2016.11.028_b0095","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.2337\/diacare.24.10.1711","article-title":"Influence of intensive diabetes treatment on body weight and composition of adults with type 1 diabetes in the Diabetes Control and Complications Trial","volume":"24","author":"DCCT","year":"2001","journal-title":"Diabetes Care"},{"key":"10.1016\/j.diabres.2016.11.028_b0100","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","author":"UKPDS","year":"1998","journal-title":"Lancet"},{"key":"10.1016\/j.diabres.2016.11.028_b0105","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1111\/dom.12493","article-title":"Weight-sparing effect of insulin detemir: a consequence of central nervous system-mediated reduced energy intake?","volume":"17","author":"Russell-Jones","year":"2015","journal-title":"Diabetes Obes Metab"},{"key":"10.1016\/j.diabres.2016.11.028_b0110","first-page":"1","article-title":"Perceptions of diabetes control among physicians and people with type 2 diabetes uncontrolled on basal insulin in Sweden, Switzerland, and the United Kingdom","volume":"7","author":"Brod","year":"2016","journal-title":"Curr Med Res Opin"},{"key":"10.1016\/j.diabres.2016.11.028_b0115","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1111\/dme.12592","article-title":"Acknowledging and allocating responsibility for clinical inertia in the management of Type 2 diabetes in primary care: a qualitative study","volume":"32","author":"Zafar","year":"2015","journal-title":"Diabet Med"}],"container-title":["Diabetes Research and Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716317363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168822716317363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,19]],"date-time":"2022-06-19T16:08:37Z","timestamp":1655654917000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168822716317363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":23,"alternative-id":["S0168822716317363"],"URL":"https:\/\/doi.org\/10.1016\/j.diabres.2016.11.028","relation":{},"ISSN":["0168-8227"],"issn-type":[{"value":"0168-8227","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Exploring the characteristics of suboptimally controlled patients after 24weeks of basal insulin treatment: An individualized approach to intensification","name":"articletitle","label":"Article Title"},{"value":"Diabetes Research and Clinical Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.diabres.2016.11.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 The Author(s). Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}